






Childrens Hospital Los Angeles	Pathology
biospecimen	
data	
↓ clinically useful knowledge	



















































Children's Hospital Los ANGELES.	USC University of
	The Variant Call Format (VCF) Version 4.2 Specification
	25 Sep 2017
	The master version of this document can be found at https://github.com/samtools/hts-specs. This printing is version c8b9990 from that repository, last modified on the date shown above.
1	The VCF specification
line,	⁷ is a text file format (most likely stored in a compressed manner). It contains meta-information lines, a header and then data lines each containing information about a position in the genome. The format also has the ability ontain genotype information on samples for each position.
#fil ##eo1 ##co1 ##co1 ##co1 ##co1 ##co1 ##co1 ##co1 ##co1 ##co1 #fil #fil #fil #fil #fil #fil #fil #fil	Advances/Description-Control (1997) - 1. store-7000000 store-7000000 store-7000000 store-7000000 store-7000000 store-7000000 store-7000000 store-7000000 store-7000000 store-7000000 store-7000000 store-7000000 store-7000000 store-7000000 store-7000000 store-700000000 store-70000000 store-700000000 store-7000000000 store-7000000000000000000000000000000000000




















Children's Hospital Los'ANGELES	ia	
LOS ANGELES. Southern Camorn	ia.	
S NCBI Resources 🗹 How To 🗹		Sign in to NCBI
ClinVar ClinVar Search ClinVa	r for gene symbols, HGVS expressions, conditions, and	more Search
Advanced		Help
Home About • Access • Help • Submit •	Statistics V FTP V	
ACTGATGGTATGGGGGCCAAGAGATATATCT	ClinVar	
CAGGTACGGCTGTCATCACTTAGACCTCAC	Ginival	
CAGGGCTGGGCATAAAAGTCAGGGCAGAGC CCATGGTGCATCTGACTCCTG <mark>A</mark> GGAGAAGT	ClinVar aggregates information about genomic variation and	d its relationship to human health.
GCAGGTTGGTATCAAGGTTACAAGACAGGT		
GGCACTGACTCTCTCTGCCTATTGGTCTAT		
Using ClinVar	Tools	Related Sites
About ClinVar	ACMG Recommendations for Reporting of Incidental Findings	ClinGen
Data Dictionary	ClinVar Submission Portal	GeneReviews ®
Downloads/FTP site	Submissions	GTR®
FAQ	Variation Viewer Clinical Remapping - Between assemblies and RefSeqGenes	MedGen
Contact Us RSS feed/What's new?	RefSegGene/LRG	OMIM ® Variation
Factsheet	KeisegGene/LKG	vanauon
racisiteei		








Nage & Chevroly Conductors have Manada shared reads and the second second second Second Second Second Manada Second Second Second Manada Second Secon										
lariant aliale frequency					Math	/	//	No match	- 1	
NO OSINC 2000 (Constraint) SIGN Professional Constraint) Constraint (Constraint) Survey France Straint) Straint (Edit Straint)	٩	Papelities transmission								P • He match
ACMO IS Silgene Int NOT In IS Silgene Int Pat	A MVL CleVer Reports + 1.55 Receptorymous P427 Nor	opronymous PoLPAVLC	Synorymous	ene Structure • «16 tip (deep inteniic)		nadig ar NAF 118 NAF 14 18 In Pina		Zygosity		a varsó vary 🛛 Hamazygaus 🖉 Possible
Gene · P	Vesilion I Ref P	ateri	Depth 207	· Tope	* Transcript NM_000201.1	* «CNA 4.9/56×A	Q maria	· Exer	Effect	 Pretein p.Trx225*
81/DC 81/DC 81/DC	171,621,279 Q, E		207	in sto	NM_000091.1	5.677.0-3	Q sono Q sono		synonymeus	p 11/2204
evoc 🐰 🕷 🗉	171421 713 0	a a	115	da ano	NM_00000411	 NET#0 	Q annin		synonymesis	p.Proble
NON 🗧 🕷 🕯	196,037,078 Q X	8 1	128	in ano	NM_031805.2	6.7818C+T	Q, morio	50	synonymous	p.Thr2606+
MON 🐻 🐿 1	186,101,810 Q. G	<u>a</u> <u>a</u>		ils sep	NM_031835.2	6.132810×C	Q, maria	86	eynorymous	p.58044274
eq 🖥 🐐 1 (297) 🖉 🗞 2	211.842.877 Q, B	88	60	in sto	> NM_002407.5	e.0830+A	Q, econo		constrontinona	p.Arg2500H
2017) 📅 🖏 2 Nana 🔐 🖏 2	29.007.010 Q 0		39	inte ano	NM_001029083.2	6.37090+A a.1600-7	Q, eorio Q, earia	2	synonymous nennymenymene	p Leu 1253+
xx7	43.898.390 Q	OCAO O	42	in restor	NM. 000332.3	6 118. 119/ta400400000	Q, erorio		infame	a On39, Pro4Dra/OnOnPro
NY 8 % 2	C2.090.290 Q .	0000-0	42	insection	NM_000223.2	6 120_125sep600900	Q, sono	2	intarre	p.Pro42_Pro43dup
tear 🐻 🐐 3:	43.598.590 Q, 🚪	8 5	26	in sto	• NM_000333.3	6 11642C	Q, exerie	8	renayronymous	p (0ie39%e
R+P2+CADH 🔖 2	1122.405.074 Q, A		35	deletion	NR_007004.1	n.2122-43e/T	Q noRNA_intronic	21		
	100.460.01% Q, B (651.200 Q, Q		100	im secon	 MM_000203.0 	5.01/0 HORI	Q, mana Q, intensi	66		
Ran 🐻 🕷 🔦	6.303,346 Q Q		208	in so	NM_000005.2	6.1728GHA	Q, sono		ransynonymous	p.Gryd7t6Ger
2024 8 % 4	15.568.552 Q. 0	a _	140	its deaton	NM_001080822.2	6.41726e/3	Q, anamio	33	Parreshill	p-01y1304/why17
CI 🚺 🐝 7.		<u>8</u>	122	in 10	> NM_001252678.1	e 3098C>T c 271Mar0	Q, eronio	23	synonymous	p He1032*
A1540 🔤 🐃 7. A1540 📓 🐃 7.		5 G 9 B	220	ile ano ile ano	 NM_001164865.1 NM_001164865.1 	6.11220-1	Q, sorio Q, sorio	2	nonsytonymous nensytonymous	p Ser900Gly p.ArgR08Cys
1.1	192,495,771 Q Q		205	in 110	NM_\$70057.5	658070+A	Q eorio	4	renevronymous	p.Ala19400y





Category	Therapeutic	Diagnosis	Prognosis
Level A	 Biomarkers that predict response or resistance to FDA-approved therapies for a specific type of tumor Biomarkers included in professional guidelines that predict response or resistance to therapies for a specific type of tumor 	Biomarkers included in professional guidelines as diagnostic for a specific type of tumor	Biomarkers included in professional guidelines as prognostic for a specifi type of tumor
Level B	Biomarkers that predict response or resistance to therapies for a specific type of tumor based on well-powered studies with consensus from experts in the field	Biomarkers of diagnostic significance for a specific type of tumor based on well-powered studies with consensus from experts in the field	Biomarkers of prognostic significance for a specific type of tumor based o well-powered studies with consensu from experts in the field
Level C	 Biomarkers that predict response or resistance to therapies approved by the FDA or professional societies for a different type of tumor Biomarkers that serve as inclusion criteria for clinical trials 	Biomarkers of dragnostic significance based on the results of multiple small studies	Biomarkers of prognostic significance based on the results of multiple sma studies
Level D	Biomarkers that show plausible therapeutic significance based on preclinical studies	Biomarkers that may assist disease diagnosis themselves or along with other biomarkers based on small studies or a few case reports	Biomarkers that may assist disease prognosis themselves or along with other biomarkers based on small studies or a few case reports

